제일약품

271980KOSPI의약품 제조업

61.8 / 100

Reference Date: 2026-04-13

Financial Score26.5 / 40

News Sentiment16.3 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Declined 11.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharm was established in 2017 through a spin-off from Jeil Pharma Holdings, focusing on the manufacturing and sales of finished pharmaceutical products. Its subsidiary, Oncol Therapeutics, specializes in new drug development. Key products include treatments for hypercholesterolemia, hyperlipidemia, and gastric cancer, with major revenue contributors being Lipito tablets and Lyrica capsules.

Number of Employees

1,011people

Average Salary

63.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.08Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.78Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

13.61Industry Average 4.427.0Point

3.1x industry avg (excellent)

Debt Ratio

6.81Industry Average 11.985.0Point

Lower than industry avg (good)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼53.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 8Neutral 0Negative 0Average Sentiment Score 66.9

Positive
[인사] 제일파마홀딩스
제일파마홀딩스가 임원 인사 및 일부 조직개편을 단행하며 제일약품의 전무, 상무, 이사 선임을 발표했습니다.
Positive
제일파마홀딩스, 경영지원본부 신설…계열사 임원 인사도 단행
제일파마홀딩스가 경영지원본부를 신설하고 임원 인사를 단행하여 경영관리 체계의 전문성 강화와 운영 효율성 극대화를 추진하고 있습니다.
Positive
성석제 제일약품 대표, 사내이사로 재선임…"자규보 기반 성장 기반 .....
성석제 제일약품 대표가 사내이사로 재선임되었고, 지난해 매출액, 영업이익, 당기순이익이 개선되었으며, 신약 '자규보'를 기반으로 성장 기반을 마련할 계획이라는 내용입니다.

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 13,230Won52-week high 17,39052-week low 12,000

1-month return1.0Point

1m -11.51% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]정기주주총회결과2026-03-25
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-24
Neutral정기주주총회결과2026-03-24
Neutral사업보고서 (2025.12)2026-03-16
Neutral감사보고서제출2026-03-16